In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...
This week’s clinical update looks at 3 clinical trials for the treatment of sickle cell disease (SCD), relapsed or refractory blood cancers and...
This week’s clinical update looks at 3 clinical trials for CRISPR-edited CAR T therapies for the treatment of B-cell cancers or multiple myeloma.
This week’s gene-editing clinical trial update looks at a universal dual specificity CD19 and CD20/CD22 CAR-T cell immunotherapy that is being...
This year CRISPR broke new ground in medicine. We saw the first CRISPR gene editing directly in the body, CRISPR took huge wins in clinical trials and...
A disease model using patients’ own cells demonstrates that prime editing can be used for functional repair of mutations leading to metabolic...
Lack of efficient delivery vehicles has so far hampered CRISPR-Cas9 editing in non-liver tumours. With a new lipid nanoparticle delivery system,...
We have added a new cancer immunotherapy trial by CRISPR Therapeutics to our overview of current clinical trials involving gene editing.
